HK1225316A1 - 治療病毒感染的方法 - Google Patents

治療病毒感染的方法

Info

Publication number
HK1225316A1
HK1225316A1 HK16113767A HK16113767A HK1225316A1 HK 1225316 A1 HK1225316 A1 HK 1225316A1 HK 16113767 A HK16113767 A HK 16113767A HK 16113767 A HK16113767 A HK 16113767A HK 1225316 A1 HK1225316 A1 HK 1225316A1
Authority
HK
Hong Kong
Prior art keywords
methods
viral infections
treating viral
treating
infections
Prior art date
Application number
HK16113767A
Other languages
English (en)
Inventor
Ernest Randall Lanier
Merrick R Almond
George R Painter
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of HK1225316A1 publication Critical patent/HK1225316A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16113767A 2008-01-25 2016-12-01 治療病毒感染的方法 HK1225316A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2363308P 2008-01-25 2008-01-25
US10181008P 2008-10-01 2008-10-01

Publications (1)

Publication Number Publication Date
HK1225316A1 true HK1225316A1 (zh) 2017-09-08

Family

ID=40901582

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11105360.8A HK1151237A1 (zh) 2008-01-25 2011-05-30 治療病毒感染的方法
HK16113767A HK1225316A1 (zh) 2008-01-25 2016-12-01 治療病毒感染的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11105360.8A HK1151237A1 (zh) 2008-01-25 2011-05-30 治療病毒感染的方法

Country Status (12)

Country Link
US (1) US8993542B2 (zh)
EP (2) EP3085377A1 (zh)
JP (1) JP5562255B2 (zh)
CN (3) CN102670628B (zh)
AU (1) AU2009206673B2 (zh)
CA (1) CA2713105C (zh)
ES (1) ES2572631T3 (zh)
HK (2) HK1151237A1 (zh)
IL (2) IL207170A (zh)
MX (1) MX2010008148A (zh)
WO (2) WO2009094191A2 (zh)
ZA (1) ZA201005737B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2534150T3 (en) 2010-02-12 2017-06-12 Chimerix Inc METHODS OF TREATING VIRUS INFECTION
WO2011139709A2 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
AU2013286704A1 (en) * 2012-07-03 2015-01-22 Chimerix, Inc. Method of treating retroviral infections and related dosage regimes
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US20150322413A1 (en) 2012-11-27 2015-11-12 Saint Louis University Hbv rnase h purification and enzyme inhibitors
JP6462659B2 (ja) 2013-03-15 2019-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非環式ヌクレオシドホスホン酸ジエステル
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
WO2015085256A1 (en) * 2013-12-05 2015-06-11 Chimerix, Inc. Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof
ES2915381T3 (es) 2014-09-15 2022-06-22 Univ California Análogos de nucleótidos
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
WO2017124895A1 (zh) * 2016-01-19 2017-07-27 四川海思科制药有限公司 一种核苷类似物的烷氧烷基酯前药及其应用
KR102272235B1 (ko) * 2016-05-12 2021-07-01 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
WO2018191579A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
TW201912153A (zh) * 2017-08-30 2019-04-01 加拿大商愛彼特生物製藥公司 用於治療ｂ型肝炎的化合物、醫藥組合物及方法

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) * 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE1248654B (de) * 1964-11-11 1967-08-31 Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) Verfahren zur Herstellung von Phosphonsäuren und deren Salzen
DE2009341C3 (de) 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3164332D1 (en) * 1980-10-21 1984-07-26 Boehringer Mannheim Gmbh Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds
CS220713B1 (cs) 1981-06-02 1983-04-29 Antonin Holy Dialkylestery kyseliny p-toluensulfonyloxymethanfosfonové a způsob jejich přípravy
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
JPS61152694A (ja) 1984-12-27 1986-07-11 Toyama Chem Co Ltd 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩
US6448392B1 (en) * 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8530603D0 (en) * 1985-12-12 1986-01-22 Leo Pharm Prod Ltd Chemical compounds
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5247085A (en) * 1987-11-30 1993-09-21 Beecham Group P.L.C. Antiviral purine compounds
SU1548182A1 (ru) * 1987-12-29 1990-03-07 Институт молекулярной биологии АН СССР 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) * 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
IL91362A0 (en) * 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
US5196409A (en) * 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IT1241674B (it) * 1989-10-12 1994-01-27 Boehringer Biochemia Srl Acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono.
DE3934820A1 (de) 1989-10-19 1991-04-25 Boehringer Mannheim Gmbh Verwendung von lecithin-analoga als antivirale arzneimittel und neue derivate
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE3942933A1 (de) 1989-12-23 1991-06-27 Boehringer Mannheim Gmbh Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
CA2083961A1 (en) * 1990-05-29 1991-11-30 Henk Van Den Bosch Synthesis of glycerol di- and triphosphate derivatives
EP0574386B1 (en) 1990-08-10 2000-06-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Novel process for the preparation of nucleotides
DE4026265A1 (de) * 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
FI89365C (fi) * 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
US5879700A (en) 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
JP3141053B2 (ja) * 1991-12-26 2001-03-05 アベンティス ファーマ株式会社 ビスホスホン酸誘導体
SK144694A3 (en) * 1992-05-29 1995-06-07 Procter & Gamble Pharma Thio-substituted nitrogen containing heterocyclic phosphate compounds for treating calcium and phosphate metabolism
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
EP0600371B1 (de) * 1992-12-02 1999-02-03 Hoechst Aktiengesellschaft Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
AU7044894A (en) * 1993-06-10 1995-01-03 University Of North Carolina At Chapel Hill, The (phospho)lipids for combatting hepatitis b virus infection
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
EP0754046A1 (en) * 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
EP0753523A1 (en) 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
US5885973A (en) * 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
CA2195262C (en) * 1996-01-18 2005-08-09 Masaru Ubasawa Phosphonate nucleotide compounds
FR2746801B1 (fr) 1996-03-27 1998-05-07 Ceca Sa Esters phosphoriques d'alkyl ou d'acyl dianhydro-1,4:3,6-d- glucitol, procede de preparation et utilisations
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5760013A (en) * 1996-08-21 1998-06-02 National Science Council Thymidylate analogs and the use thereof
DE69737385T2 (de) 1996-12-19 2007-10-25 Kao Corp. Zusammensetzung für die beschichtung von zähnen
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6686462B2 (en) 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP0986572B2 (en) * 1997-06-06 2007-06-13 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU8828598A (en) * 1997-08-15 1999-03-08 Rubicon Laboratory, Inc. Retrovirus and viral vectors
WO1999008685A1 (en) 1997-08-18 1999-02-25 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
ATE356630T1 (de) * 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1082121A4 (en) 1998-06-03 2003-02-05 Merck & Co Inc INTEGRASE HIV INHIBITORS
JP2002516858A (ja) 1998-06-03 2002-06-11 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
FR2781228B1 (fr) 1998-07-16 2000-09-29 Pf Medicament Phosphonates insatures derives d'indole
AU764532B2 (en) 1998-07-27 2003-08-21 University Of Iowa Research Foundation, The Stereoisomers of CpG oligonucleotides and related methods
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
WO2000036132A1 (en) 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
DE19859426A1 (de) 1998-12-22 2000-07-06 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
WO2000039086A1 (fr) 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih
CN1367784A (zh) 1999-06-02 2002-09-04 盐野义制药株式会社 新的取代丙烯酮衍生物的制备方法
EP1196384A4 (en) 1999-06-25 2002-10-23 Merck & Co Inc 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
ATE419869T1 (de) 1999-08-19 2009-01-15 Dynavax Tech Corp Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
CA2385349A1 (en) 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
EE200200158A (et) 1999-09-25 2003-06-16 University Of Iowa Research Foundation Immunostimulatoorsed nukleiinhapped
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
WO2001027309A1 (en) 1999-10-13 2001-04-19 Merck & Co., Inc. Hiv integrase inhibitors
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
EP1914237B1 (en) 1999-12-03 2014-06-18 The Regents of The University of California Phosphonate ester antiviral compounds
DK1914237T3 (da) 1999-12-03 2014-09-15 Univ California Antivirale fosfonatesterforbindelser
EP1118333A1 (en) 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
CN1418077A (zh) * 2000-01-28 2003-05-14 德克萨斯大学董事会 预防性传播疾病传播的方法和器具
US20020136757A1 (en) * 2000-01-28 2002-09-26 Samuel Baron Methods and devices for preventing transmission of sexually transmitted diseases
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
CA2425067A1 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
DE60138635D1 (de) 2000-10-12 2009-06-18 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US7288265B1 (en) * 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
BR0115474A (pt) 2000-11-17 2006-01-31 Idenix Cayman Ltd Composição e método para inibição da transmissão de hiv que usam 6-benzil-4-oxopirimidinas substituìdas aplicada por via tópica
US6605602B1 (en) * 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
JP2005508945A (ja) 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
MXPA04003816A (es) 2001-10-23 2004-07-30 Ono Pharmaceutical Co Medicamento que comprende combinacion de derivado de triazaespiro[5.5]undecano con inhibidor de isozima 3a4 de citocromo p450 y/o inhibidor de p-glicoproteina.
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
CA2474056A1 (en) 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
US7462608B2 (en) * 2002-04-26 2008-12-09 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
WO2004062600A2 (en) 2003-01-08 2004-07-29 Lectec Corporation Antiviral patch
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2004096807A2 (en) 2003-04-28 2004-11-11 Tibotec Pharmaceuticals Ltd. Hiv integrase inhibitors
AU2004249250C1 (en) 2003-06-20 2012-04-12 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
CN1921867B (zh) 2004-02-17 2010-05-05 株式会社Lg生命科学 用于治疗hiv感染的膦酸核苷衍生物
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
WO2006076015A2 (en) * 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
US8541167B2 (en) * 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20080113031A1 (en) * 2004-09-27 2008-05-15 Joey Moodley Minicapsule Formulations
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP2842559A3 (en) * 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
JP5320284B2 (ja) * 2006-05-03 2013-10-23 キメリクス，インコーポレーテッド 抗ウイルス性または抗増殖性のホスホネート、ヌクレオシドホスホネートおよびヌクレオシドホスフェートの代謝安定性アルコキシアルキルエステル
ES2546378T3 (es) 2006-07-07 2015-09-23 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
EP2046792B1 (en) 2006-07-12 2015-02-25 Mylan Laboratories Limited Process for the preparation of tenofovir
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
EP2308514B1 (en) 2007-03-23 2013-06-05 to-BBB Holding B.V. Conjugates for targeted drug delivery across the blood-brain barrier
CN101678122A (zh) 2007-04-27 2010-03-24 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
WO2008133982A2 (en) 2007-04-27 2008-11-06 Lectec Corporation Adhesive patch with aversive agent
WO2008144743A1 (en) 2007-05-21 2008-11-27 Saint Louis University Screening tool for antiviral agents
US20090111774A1 (en) * 2007-06-01 2009-04-30 Luitpold Pharmaceuticals, Inc. Pmea lipid conjugates
CA2711424A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
EP2240504A1 (en) * 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US20120164104A1 (en) 2009-08-03 2012-06-28 Chimerix, Inc. Composition and Methods of Treating Viral Infections and Viral Induced Tumors
AU2010313273B2 (en) 2009-10-30 2015-04-02 Emergent Biodefense Operations Lansing Llc Methods of treating viral associated diseases
DK2534150T3 (en) * 2010-02-12 2017-06-12 Chimerix Inc METHODS OF TREATING VIRUS INFECTION

Also Published As

Publication number Publication date
IL207170A0 (en) 2010-12-30
AU2009206673A1 (en) 2009-07-30
CN105055432A (zh) 2015-11-18
US8993542B2 (en) 2015-03-31
CN101977610B (zh) 2012-05-16
WO2009094190A3 (en) 2009-10-01
IL242518A (en) 2017-07-31
CA2713105C (en) 2016-06-07
JP2011510077A (ja) 2011-03-31
JP5562255B2 (ja) 2014-07-30
MX2010008148A (es) 2010-10-20
ZA201005737B (en) 2012-04-25
IL207170A (en) 2016-11-30
WO2009094191A3 (en) 2009-10-01
WO2009094190A2 (en) 2009-07-30
HK1151237A1 (zh) 2012-01-27
EP3085377A1 (en) 2016-10-26
CN102670628B (zh) 2015-11-25
AU2009206673B2 (en) 2015-04-23
ES2572631T3 (es) 2016-06-01
EP2254582A4 (en) 2011-07-20
CN101977610A (zh) 2011-02-16
EP2254582A2 (en) 2010-12-01
US20110021464A1 (en) 2011-01-27
CN102670628A (zh) 2012-09-19
WO2009094191A2 (en) 2009-07-30
EP2254582B1 (en) 2016-01-20
CA2713105A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
HK1225316A1 (zh) 治療病毒感染的方法
HK1250936A1 (zh) 用於治療病毒感染的化合物和方法
HK1144794A1 (zh) 病毒感染治療用裝置
IL208354A0 (en) Methods of treatment
EP2334328A4 (en) METHOD FOR CLEANING VIRUSES
GB0816679D0 (en) Compounds for treating viral infections
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
HK1183487A1 (zh) 用於治療副黏病毒科病毒感染的方法和化合物
EP2462152A4 (en) COMPOSITION AND METHODS FOR TREATING VIRAL INFECTIONS AND TUMORS OF VIRAL ORIGIN
EP2493479A4 (en) METHOD FOR THE TREATMENT OF VIRUS DISEASES
EP2350641A4 (en) Methods of Treatment
EP2521554A4 (en) SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
EP2534150A4 (en) METHODS OF TREATING A VIRAL INFECTION
DK2473482T3 (en) Methods of treating orthomyxoviral infections
EP2473493A4 (en) METHODS OF TREATING POXVIRAL INFECTIONS
EP2424559A4 (en) METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS WITH ORITAVANCIN
EP2663327A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2164494A4 (en) Methods of Treatment
EP2429290A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF AIDS AND HIV INFECTIONS
IL205035A0 (en) Methods of inhibiting viral infection
IL204940A0 (en) Methods of inhibiting viral infection
GB0919711D0 (en) Treatment of viral infections
GB0913914D0 (en) Treatment of viral infections
EP2403496A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS
GB0813716D0 (en) Treatment of viral infection